A recent research report published by MarkNtel Advisors states that the Global Immune Checkpoint Inhibitors Market could grow at around 17% CAGR during 2022-27. Immune Checkpoint Inhibitors are known for attacking potentially harmful agents by using the immune system & turning it on to target the cancer cells.
However, these inhibitors do not kill cancer directly but help the immune system identify & attack the cells throughout the body. With the rapidly increasing cancer cases worldwide, the need for effective & safe therapies like immunotherapy is burgeoning and, in turn, fueling the demand for immune checkpoint inhibitors. It, in turn, is also instigating governments & the leading biotechnology & pharmaceutical companies worldwide to invest substantially in various R&D activities to bring innovations in inhibitors and cater to the unmet healthcare needs of patients.
Moreover, the positive & revolutionizing effects of immune checkpoint inhibitors on advanced cancer cases like Melanoma & Non-Small Cell Lung Cancer are also propelling the demand for immune checkpoint inhibitors & encouraging the leading players to launch novel drugs for better treatments & patient outcomes, which project numerous growth opportunities for the global market in the years to come, further states the research report, “Global Immune Checkpoint Inhibitors Market Analysis, 2022.”
High Efficacy & Safety of PD-1 Inhibitors to Drive the Global Market
PD-1 inhibitors are anticipated to dominate the Global Immune Checkpoint Inhibitors Market with the largest share during the forecast period, principally due to the increasing government support in bringing innovations in PD-1 inhibitors like Opdivo (Nivolumab) & Keytruda (Pembrolizumab) through various R&D activities, coupled with rapid approvals by different regulatory associations worldwide.
Besides, with the mounting influx of cancer patients and their inclination toward immunotherapy as a treatment, the prescription for Nivolumab & Pembrolizumab drugs is escalating swiftly for their efficiency in addressing indications like Melanoma, Non–Small Cell Lung Cancer (NSCLC), Head & Neck Squamous Cell Cancer (HNSCC) and, in turn, augmenting the overall market growth.
With Massive Patient Pool for Cancer, Asia-Pacific to Lead the Immune Checkpoint Inhibitors Market
The Asia-Pacific Immune Checkpoint Inhibitors Market is likely to be the largest of all regions globally during 2022-27. The immense pool of cancer patients and the growing healthcare expenditure by governments of countries like China, Japan, & India, among others, are leading to the surging demand for immune checkpoint inhibitors across Asia-Pacific, backed by the mounting penetration of immunotherapy treatments.
The same aspect is consequently portraying the active participation of leading biopharma companies in multiple research & development activities for bringing innovations in existing therapies and new medications with greater efficacy & safety. Furthermore, a growing number of collaborations, partnerships, and mergers & acquisitions between the leading companies with numerous local players to expand their scalability & product portfolio across Asia-Pacific are further fueling the growth of the regional market.
The major companies in the Global Immune Checkpoint Inhibitors Market include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bluebird Bio, Inc., Bristol Myers Squibb, CARsgen Therapeutics, Eli Lilly and Company, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., and Sun Pharmaceutical Industries Ltd.
Key Questions Answered in the Research Report